SML4089

VU534

≥98% (HPLC)

• Synonym(e): N-(5,7-Dimethyl-2-benzothiazolyl)-1-[(4-fluorophenyl)sulfonyl]-4-piperidinecarboxamide, VU 534, VU-534
• Empirische Formel (Hill-System): C₂₁H₂₂FN₃O₃S₂
• CAS-Nummer: 923509-20-0
• Molekulargewicht: 447.55
• MDL number: MFCD09248208
• NACRES: NA.21
• UNSPSC Code: 12352200
• Assay: ≥98% (HPLC)
• Form: powder

Eigenschaften

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear (Warmed)
• storage temp.: 2-8°C
• SMILES string: O=C(C1CCN(S(=O)(C2=CC=C(C=C2)F)=O)CC1)NC3=NC4=C(S3)C(C)=CC(C)=C4

Beschreibung

Biochem/physiol Actions

Allosteric site-targeting, reversible, potent and selective N-Acyl-phosphatidylethanolamine-hydrolyzing phospholipase D (NAPE-PLD) activator.

VU534 is a non-cytotoxic (up to 30 μM in murine RAW264.7 and human HepG2 cultures), reversible, potent and selective N-Acyl-phosphatidylethanolamine-hydrolyzing phospholipase D activator (mouse EC50/Emax = 0.30 μM/2.1-fold, human EC50/Emax = 0.93 μM/1.8-fold, using respective recombinant NAPE-PLD) that targets an allosteric site distinct from that of PE, DCA, or LEI-401, showing only weak sEH inhibition (IC50/Emax = 1.2 μM/55%) and little potency toward FAAH. VU534 enhances murine BMDMs efferocytosis (by 1.65-fold with 6h 10 μM pretreatment) by activating cellular NAPE-PLD activity (EC50/Emax = 6.6 μM/1.6-fold in RAW264.7 and 1.5 μM/1.6-fold in HepG2).

Sicherheitshinweise

• Piktogramme: GHS07
• Signalwort: Warning
• Gefahrencodes: H302
• Sicherheitshinweise: P264 - P270 - P301 + P312 - P501
• Hazard Classifications: Acute Tox. 4 Oral
• Lagerklasse: 11 - Combustible Solids
• Was ist los?: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable